Heron Therapeutics appoints Mark Hensley as COO effective April 28, 2025

HERON THERAPEUTICS, INC. /DE/

Annual base salary of $553,000; target cash bonus of $276,500 (50% of base), prorated for 2025.
Inducement awards: option for 500K shares, 500K RSUs, and performance option for up to 900K shares.
Vesting: option and RSUs vest over 4 years; performance option vests upon stock price goals.
Hensley previously served as CEO of Veloxis Pharmaceuticals from 2021 to 2024.
Awards granted outside 2007 Plan as material inducement under Nasdaq Rule 5635(c)(4).

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Mark Hensley

Chief Operating Officer

HRTX · HERON THERAPEUTICS, INC. /DE/

Effective: 2025-04-28
Filed: April 29, 2025, 7:59 PM ET

On April 28, 2025, Heron Therapeutics, Inc. (the “ Company ”) announced that it appointed Mark Hensley as Chief Operating Officer, effective April 28, 2025

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark Hensley was appointed as Chief Operating Officer at HERON THERAPEUTICS, INC. /DE/.

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

On April 28, 2025, Heron Therapeutics, Inc. (the “ Company ”) announced that it appointed Mark Hensley as Chief Operating Officer, effective April 28, 2025

View on SEC.gov

HERON THERAPEUTICS, INC. /DE/ filing history →

Source: SEC EDGAR

accession 0000950170-25-059479

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.